Original article

Title: Safety and immunogenicity of BNT162b2 mRNA COVID-19 vaccine in Japanese patients after allogeneic stem cell transplantation.

Marika Watanabe^{1*}, Kimikazu Yakushijin^{1*}, Yohei Funakoshi^{1*}, Goh Ohji², Hironori Sakai³, Wataru Hojo³, Miki Saeki¹, Yuri Hirakawa¹, Sakuya Matsumoto¹, Rina Sakai¹, Shigeki Nagao¹, Akihito Kitao¹, Yoshiharu Miyata⁴, Taiji Koyama¹, Yasuyuki Saito⁵, Shinichiro Kawamoto¹, Mitsuhiro Ito^{1,6}, Tohru Murayama^{1,7}, Hiroshi Matsuoka⁴, Hironobu Minami^{1,8}

* MW, KY, and YF contributed equally to this work.

1. Division of Medical Oncology/Hematology, Department of Medicine, Kobe University Hospital and Graduate School of Medicine, Kobe, Japan
2. Division of Infectious Disease Therapeutics, Department of Microbiology and Infectious Diseases, Kobe University Graduate School of Medicine, Kobe, Japan
3. R&D, Cellspect Co., Ltd., Morioka, Iwate, Japan
4. BioResource Center, Kobe University Hospital, Kobe, Japan
5. Division of Molecular and Cellular Signaling, Kobe University Graduate School of Medicine, Kobe, Japan
6. Laboratory of Hematology, Division of Medical Biophysics, Kobe University Graduate School of Health Sciences, Kobe, Japan
7. Hematology Division, Hyogo Cancer Center, Akashi, Japan
8. Cancer Center, Kobe University Hospital, Kobe, Japan

Corresponding author:

Kimikazu Yakushijin, M.D., Ph.D.

Division of Medical Oncology/Hematology, Department of Medicine, Kobe University Hospital and Graduate School of Medicine

E-mail: kyakushi@med.kobe-u.ac.jp

Phone: +81-78-382-5820, Fax: +81-78-382-5821

Running head: Evaluation of BNT162b2 for HSCT patients

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

Abstract

Patients who have undergone hematopoietic stem cell transplantation (HSCT) for hematological disease experience high mortality when infected by coronavirus disease 2019 (COVID-19). However, the safety and efficacy of COVID-19 vaccine in HSCT patients remains to be investigated. We prospectively evaluated the safety and immunogenicity of BNT162b2 mRNA COVID-19 vaccine (Pfizer BioNTech) in 25 Japanese allogeneic HSCT patients in comparison with 19 healthy volunteers. While anti-S1 antibody titers in almost all healthy volunteers after the second dose were higher than the cut-off value reported previously, levels in HSCT patients after the second dose were diverse. Nineteen patients (76%) got seroconversion of anti-S1 IgG. Median optical density of antibody levels in HSCT patients with low IgG levels (< 600 mg/dL), steroid treatment, or low lymphocytes (< 1000 / μ L) was significantly lower than that in the other HSCT patients. There were no serious adverse events ($> \text{Grade } 3$), no new development or exacerbation of graft-versus-host disease after vaccination. We concluded BNT162b2 mRNA vaccine is safe and effective in Japanese allogeneic HSCT patients.

Key words: Hematopoietic stem cell transplantation, BNT162b2, COVID-19, Vaccination

Introduction

Patients with previous hematopoietic stem cell transplantation (HSCT) who are affected by coronavirus disease 2019 (COVID-19) are reported to have a high mortality rate of around 30% ¹. HSCT patients are known to be highly immunocompromised due to past chemotherapy or immunosuppressive agents for graft-versus-host disease (GVHD). Prevention of COVID-19 is therefore critically important in these patients.

The BNT162b2 mRNA COVID-19 vaccine (Pfizer BioNTech) was developed in 2020 and induces robust antibody and T cell responses for SARS-CoV-2 ². The phase 3 trial of this vaccine reported 95% efficacy in preventing symptomatic COVID-19 ³. However, the safety and efficacy of this vaccine for HSCT patients remain to be investigated because these patients were excluded from the initial registration trials. Some studies have reported the safety and efficacy of SARS-CoV-2 vaccines for HSCT patients ⁴⁻⁶. Efficacy and safety need to be determined with regard to allogeneic transplantation and ethnic differences, as is also the case with GVHD ⁷. A pivotal study showed that Asian people tended to have lower vaccine efficacy than other ethnicities, albeit that the difference is not significant ⁸. Further, racial variation in the major histocompatibility complex molecules may affect the results of vaccination ⁹. With regard to safety, it has been reported that BNT162b2 might induce controllable GVHD or cytopenia with mixed chimerism between donor and recipient ¹⁰, but the safety and immunogenicity of the COVID-19 vaccines for Japanese patients who have undergone HSCT is unclear.

Here, we prospectively investigated the safety and immunogenicity of BNT162b2 in Japanese patients who had undergone HSCT.

Patients and Methods

Study design

Patients who had undergone HSCT at Kobe University Hospital were enrolled, together with healthy volunteer controls. All patients who were at least three months after transplantation and who gave written informed consent to participate in the study between March 2021 and August 2021 were included. All participants were vaccinated with 2 doses of BNT162b2 with a 3-week interval. Peripheral blood samples were collected at pre-vaccination (within 14 days prior to the first dose), and within 7 days prior to the second dose and 14 days (+/- 7 days) after the second dose of BNT162b2. Exclusion criteria included a documented COVID-19 infection within 14 days after the second dose. Vaccine-related adverse events were evaluated by Common Terminology Criteria for Adverse Events 5.0 except for fever, which we defined as Grade 1 37.5–37.9 °C, Grade 2 38.0–38.9 °C, Grade 3 39.0–39.9 °C and Grade 4 ≥ 40.0 °C in the armpit. This study was approved by the Kobe University Hospital Ethics Committee (No. B2056714) and was conducted in accordance with the Declaration of Helsinki. All participants provided written informed consent for this study.

Sample collection and measurement of antibody titers

Serum samples were obtained by centrifugation of blood samples at $1000 \times g$ for 10 min at room temperature and immediately transferred to a freezer kept at -80°C .

Antibody titers against S1 were measured using the QuaResearch COVID-19 Human IgM IgG ELISA kit (Spike Protein-S1) (Cellspect, Inc., RCOEL961S1, Iwate, Japan). This kit is based on the indirect ELISA method and comes with different immobilized antigenic proteins. The plate of the ELISA kit (Spike Protein-S1) is immobilized with a recombinant spike protein (S1, 251-660AA) of SARS-CoV-2 expressed in *Escherichia coli*. Serum samples were diluted 1:200 in 1% BSA/PBST for RCOEL961S1. The plates were read at 450 nm with an SH-1200 plate reader (Corona Electric Co. Ltd.) in accordance with the manufacturer's protocol. Based on the previous report¹¹, the optimal optical density (O.D.) cut-off value of anti-S1 IgG antibody for seroconversion was determined as 0.26.

Statistical analysis

Categorical and continuous variables were compared using Fisher's exact test and the Mann-Whitney *U* test, respectively. Pearson's test was used to evaluate correlations between lymphocyte count and IgG level. All statistical tests were two-sided, and were performed using STATA (version 17.0; Stata Corp, TX) and EZR (Saitama Medical Center, Jichi Medical University, Saitama, Japan), a graphical user interface for R (The R Foundation for Statistical Computing, Vienna, Austria)¹² at $P < 0.05$ as level of significance.

Results

Patient characteristics

Twenty-five patients who underwent HSCT and nineteen healthy volunteers were included in this study. Patient characteristics are shown in Table 1. Median age of the HSCT patients was 55 years (range, 23–71 years) at the time of the first dose and 11 patients were female. Median duration between HSCT and vaccination was 1605 days (range, 163–4126 days). Only one patient who received rituximab therapy was included, and the last administration was over five years ago. Seven patients were receiving immunosuppressants at the time of the first vaccination. Two of these seven patients were taking tacrolimus alone and one was receiving tacrolimus plus concomitant steroids. Three patients took steroids alone and the other received both cyclosporine and steroid for nephrotic syndrome. Hematological disease status was stable in all patients, and none had developed COVID-19 prior to the first dose. Median level of serum IgG was 1087 mg/dL (range, 181–2169) and median absolute lymphocyte count was 2320 / μ L (range, 309–4998). Regarding the 19 healthy volunteers used as control (female, $n = 7$), median age was 74 years (range, 39–82) and none had developed COVID-19 infection prior to the study.

Serological outcomes

Anti-S1 IgG antibody titers in healthy volunteers were all significantly higher after the second dose than at pre-vaccination and they all except for one participant got seroconversion. In contrast,

titers in HSCT patients after the second dose were diverse. The median O.D. of anti-S1 IgG antibody titers after the second dose in HSCT patients and in the healthy volunteer group were 0.540 (range, 0.016–1.991) and 0.687 (range, 0.259–1.498), respectively ($P = 0.41$) (Figure 1). Nineteen patients (76%) had higher anti-S1 antibody titers than 0.26.

Results for HSCT patients by subgroup are shown in Figure 2. The median O.D. of antibody levels in patients with a high or low IgG level ($\geq$ or < 600 mg/dL), with or without steroid treatment, and with high or low lymphocytes ($\geq$ or < 1000 / μ L) were 0.739 (range, 0.037–1.991) vs 0.097 (range, 0.016–0.417) ($P = 0.01$), 0.7655 (range, 0.037–1.991) vs 0.121 (range, 0.016–0.417) ($P = 0.01$), and 0.792 (range, 0.037–1.991) vs 0.2625 (range, 0.016–0.509) ($P = 0.01$), respectively. However, we found a moderate correlation between lymphocyte count and IgG titer ($r = 0.651$). There was no significant difference in anti-S1 IgG antibody titer between the group taking calcineurin inhibitors and those not taking them ($P = 0.45$). Multivariate analyses could not be performed due to the small number of cases.

The scatter plot of anti-S1 IgG titers by days from HSCT to first immunization is shown in Figure 3. Four patients received vaccination within one year after HSCT, two of whom had higher anti-S1 antibody titers than 0.26. Of the 21 patients who received vaccination more than one year after HSCT, 17 (81%) had anti-S1 antibody titers higher than 0.26 ($P = 0.23$).

Safety

Data on vaccine-related adverse events are shown in Table 2. No serious adverse event (> Grade 3) was reported in any participant. The most frequent adverse event was pain at the injection site. Adverse events after the second dose were slightly worse than those after the first dose in our HSCT patients. In this study, no newly diagnosed GVHD or GVHD exacerbation was encountered after vaccination.

Discussion

We prospectively investigated the safety and immunogenicity of BNT162b2 in Japanese HSCT patients. Six patients yielded lower antibody levels than 0.26. However, 76% of the patients obtained sufficient immunogenicity. Recent studies have reported that seroconversion after 2 doses of vaccination reaches 75–86% in allogeneic HSCT patients ^{5,10,13-16}; our present results are consistent with this level. In one previous report, the main factor influencing vaccination response was the time elapsed from HSCT, with lower responses occurring within one year from HSCT ¹³. In our present subjects, one of four patients vaccinated within one year from transplantation had an apparently low antibody titer, and no association with antibody titer was seen for interval since transplantation and first dose.

Immunosuppressive therapy ¹⁴⁻¹⁶ and chronic GVHD ^{14,16} at vaccination are reported to be associated with a low response to SARS-CoV-2 vaccination. In our cohort, only three patients had developed chronic GVHD and were taking steroids. Additionally, one patient received steroid and

cyclosporin against nephrotic syndrome. In our study, calcineurin inhibitors were not associated with low response to vaccination, whereas low total lymphocyte count, steroid use, and low total IgG level were associated with poor response to vaccination; however, we were unable to perform multivariate analyses because of the small number of the cases. Calcineurin inhibitors are known to suppress T lymphocytes mainly, because of which there might be no differences of anti-S1 IgG titers with or without calcineurin inhibitors.

In our cohort, all adverse events were mild, and pain at the injection site was the most common event, as previously reported ¹⁴⁻¹⁶. A recent study reported that approximately 10% of patients developed cytopenia after each dose, which resolved within two weeks ¹⁰. As we did not routinely perform blood examination one week after each dose, we might not have been able to detect cytopenia as an adverse event. In terms of GVHD, while exacerbation or development of GVHD was observed in some previous reports ^{10,14,16}, only a few patients (4.5%) experienced exacerbation of GVHD, all cases of which developed within the first week after injection in one report ¹⁰. In that report, all cases of GVHD exacerbation were easy to control. In our study, no patient developed GVHD or experienced exacerbation of GVHD, which suggests that BNT162b2 could be also safely administered to Japanese HSCT patients. Interestingly, the possibility that a third vaccination may be effective without reactivation of GVHD was recently reported ¹⁷. In our cohort, there were six patients who did not obtain sufficient immunogenicity; a third vaccination should be considered in patients who seem unlikely to acquire sufficient immunity with two doses of vaccination, albeit that further investigation

of this possibility is required.

Several limitations of our study warrant mention. First, the cohort was too small to allow multivariate analyses. Second, as the disease status in our cohort was stable, safety and immunogenicity in patients with relapse or receiving high-dose steroids for acute or chronic GVHD are uncertain. Third, the precise titer border line providing clinical protection for COVID-19 remains unclear. However, we believe that many Japanese HSCT patients would have gained sufficient immunity, as did the healthy volunteers.

To our knowledge, this study is the first prospective observational study on the safety and immunogenicity of BNT162b2 in Japanese patients who received allogeneic HSCT. Most HSCT patients obtained certain immunogenicity without severe adverse events, whereas patients taking steroids or with low lymphocyte counts did not yield sufficient antibody titers. Further investigation to confirm our findings are needed, and long-term monitoring of antibody levels is warranted.

Conflicts of Interest

Hironobu Minami has received research grants and honoraria from Pfizer. Kimikazu Yakushijin has received honoraria from Pfizer. Hironori Sakai and Wataru Hojo are employed by Cellspect. The other authors declare no potential conflicts of interest.

Table 1. Patient characteristics

Median age at vaccination (Range, years)	55 (23-71)	
Sex	n	%
Female	11	44
Male	14	56
Conditioning		
MAC	9	36
RIC	16	64
Disease		
AML	11	44
ALL	6	24
ML	5	20
Others	3	12
Immunosuppressants		
Tacrolimus alone	2	8
Tacrolimus + steroid	1	4
Cyclosporine A +steroid	1	4
Steroid alone	3	12
No use	18	72
IgG		
≥ 600 mg/dl	21	84
< 600 mg/dl	4	16
Absolute lymphocyte counts		
≥ 1000 /μl	19	76
< 1000 /μl	6	24

MAC, myeloablative conditioning; RIC, reduced-intensity conditioning; AML, acute myeloid leukemia; ALL acute lymphoblastic leukemia; ML, malignant lymphoma

Table 2. Adverse events

1st dose	Patients, n (%)	HV, n (%)	<i>P</i> value
Fever	1 (4)	1 (5)	1
Pain	20 (80)	12 (63)	0.308
Redness	1 (4)	0 (0)	1
Swelling	2 (8)	2 (11)	1
Headache	4 (16)	0 (0)	0.122
Fatigue	5 (20)	4 (21)	1
Chills	2 (8)	0 (0)	0.498
Muscle pain	3 (12)	1 (5)	0.622
Joint pain	2 (8)	0 (0)	0.498
Vomiting	1 (4)	0 (0)	1
Diarrhea	1 (4)	1 (5)	1
2nd dose			
Fever	1 (4)	2 (11)	0.181
Pain	17 (68)	13 (68)	1
Redness	2 (8)	1 (5)	1
Swelling	6 (24)	2 (11)	0.433
Headache	7 (28)	1 (5)	0.111
Fatigue	13 (52)	6 (32)	0.227
Chills	2 (8)	1 (5)	1
Muscle pain	3 (12)	1 (5)	0.622
Joint pain	1 (4)	0 (0)	1
Vomiting	0 (0)	0 (0)	1
Diarrhea	1 (4)	0 (0)	1
Skin rash	1 (4)	0 (0)	1

HV, healthy volunteers

Figure

Figure 1

Figure 1. Anti-S1 antibody response at pre-vaccination (within 14 days prior to the first dose), and within 7 days prior to the second dose and 14 days (+/- 7 days) after the second dose of BNT162b2 in healthy volunteers and patients with hematopoietic stem cell transplantation.

Figure 2

Figure 2. Anti-S1 titers after the second dose in each subgroup of transplant patients. Median optical density of antibody levels in patients with low IgG levels (< 600 mg/dL), steroid treatment, and low lymphocytes (< 1000 / μ L) was significantly lower than in the other patients. There was no significant difference in S1-antibody titers between the group taking calcineurin inhibitors and the group not taking them ($P = 0.45$).

Figure 3

Figure 3. Relationship between S1 titers after the second dose and duration from transplantation to vaccination. The perforated line indicates the threshold (0.26) for seroconversion.

References

1. Sharma A, Bhatt NS, St Martin A, et al. Clinical characteristics and outcomes of COVID-19 in haematopoietic stem-cell transplantation recipients: an observational cohort study. *The Lancet Haematology*. 2021;8(3):e185-e193.
2. Arunachalam PS, Scott MKD, Hagan T, et al. Systems vaccinology of the BNT162b2 mRNA vaccine in humans. *Nature*. 2021;596(7872):410-416.
3. Polack FP, Thomas SJ, Kitchin N, et al. Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine. *The New England journal of medicine*. 2020;383(27):2603-2615.
4. Ali H, Ngo D, Aribi A, et al. Safety and Tolerability of SARS-CoV2 Emergency-Use Authorized Vaccines for Allogeneic Hematopoietic Stem Cell Transplant Recipients. *Transplantation and cellular therapy*. 2021.
5. Hill JA. Humoral Immunity After mRNA SARS-CoV-2 Vaccination in Allogeneic HCT Recipients-Room for Improvement and Much to Learn. *JAMA network open*. 2021;4(9):e2127454.
6. Dhakal B, Abedin S, Fenske T, et al. Response to SARS-CoV-2 vaccination in patients after hematopoietic cell transplantation and CAR T-cell therapy. *Blood*. 2021;138(14):1278-1281.
7. Morishima Y, Kawase T, Malkki M, et al. Significance of ethnicity in the risk of acute graft-versus-host disease and leukemia relapse after unrelated donor hematopoietic stem cell transplantation. *Biol Blood Marrow Transplant*. 2013;19(8):1197-1203.
8. Thomas SJ, Moreira ED, Jr., Kitchin N, et al. Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine through 6 Months. *The New England journal of medicine*. 2021.
9. Liu G, Carter B, Gifford DK. Predicted Cellular Immunity Population Coverage Gaps for SARS-CoV-2 Subunit Vaccines and Their Augmentation by Compact Peptide Sets. *Cell systems*. 2021;12(1):102-107.e104.
10. Ram R, Hagin D, Kikozashvili N, et al. Safety and Immunogenicity of the BNT162b2 mRNA COVID-19 Vaccine in Patients after Allogeneic HCT or CD19-based CART therapy-A Single-Center Prospective Cohort Study. *Transplantation and cellular therapy*. 2021;27(9):788-794.
11. Imai K, Kitagawa Y, Tabata S, et al. Antibody response patterns in COVID-19 patients with different levels of disease severity in Japan. *Journal of medical virology*. 2021;93(5):3211-3218.
12. Kanda Y. Investigation of the freely available easy-to-use software 'EZ' for medical statistics. *Bone Marrow Transplant*. 2013;48(3):452-458.
13. Attolico I, Tarantini F, Carluccio P, et al. Serological response following BNT162b2 anti-SARS-CoV-2 mRNA vaccination in haematopoietic stem cell transplantation patients. *British journal of haematology*. 2021.
14. Cinti L, Humblet-Baron S, Desombere I, et al. Predictors of neutralizing antibody response to BNT162b2 vaccination in allogeneic hematopoietic stem cell transplant recipients. *J Hematol Oncol*. 2021;14(1):174.
15. Chiarucci M, Paolasini S, Isidori A, et al. Immunological Response Against SARS-COV-2 After BNT162b2 Vaccine Administration Is Impaired in Allogeneic but Not in Autologous Stem Cell Transplant Recipients. *Front Oncol*. 2021;11:737300.
16. Shem-Tov N, Yerushalmi R, Danylesko I, et al. Immunogenicity and safety of the BNT162b2 mRNA COVID-19 vaccine in haematopoietic stem cell transplantation recipients. *Br J Haematol*. 2021.

17. Le Bourgeois A, Coste-Burel M, Guillaume T, et al. Interest of a third dose of BNT162b2 anti-SARS-CoV-2 messenger RNA vaccine after allotransplant. *British journal of haematology*. 2021.